Abstract 689TiP
Background
Aurora kinase A (AURKA), a crucial mitotic regulator, is frequently dysregulated in a wide range of cancers, which contributes to clinical aggressiveness and poor patient survival, making it an attractive therapeutic target. Prior studies with pan-Aurora kinase inhibitors have shown limited success, largely owing to the narrow therapeutic window associated with bone marrow toxicity caused by targeting Aurora B. The development of highly selective AURKA inhibitors, with improved efficacy and tolerability, is highly warranted. We have developed JAB-2485, a potent, small-molecule AURKA inhibitor with greater than 1500-fold selectivity over AURKB and AURKC. JAB-2485 efficiently induced G2/M phase cell cycle arrest and apoptosis of cancer cells in vitro. Furthermore, it showed impressive anti-tumor efficacy both as a single agent and in synergy with chemotherapies in multiple animal models.
Trial design
This global first-in-human, open-label, multi-center phase 1/2a trial evaluates the safety and tolerability of JAB-2485 in adult patients with advanced solid tumors. In the dose escalation phase (phase 1), six dose levels of daily JAB-2485 (5, 10, 20, 40, 60, and 80mg) will be explored to determine the maximum tolerated dose (MTD) using a modified toxicity probability interval 2 (mTPI-2) method. After determining the recommended phase 2 dose (RP2D), the dose-expansion phase (Phase 2a) will explore the preliminary anti-tumor activity of JAB-2485 as a single agent in patients with ER+ breast cancer, triple-negative breast cancer, small cell lung cancer, and tumors harboring ARID1A mutations. The inclusion criteria for the phase 1 portion include progressive refractory advanced solid malignancy, ≥18 years of age, ECOG performance status ≤ 1, and adequate organ function. The primary endpoint is the incidence of dose-limiting toxicity (DLT) and the safety and tolerability of JAB-2485. The secondary endpoints include pharmacokinetics, overall response rate, time to, and duration, of response. Exploratory endpoints include correlative pharmacodynamic markers.Enrollment in this trial started in January 2023 in the US and April 2024 in China.
Clinical trial identification
NCT05490472; CTR20223395.
Editorial acknowledgement
Legal entity responsible for the study
Jacobio Pharmaceuticals Co., Ltd.
Funding
Jacobio Pharmaceuticals Co., Ltd.
Disclosure
V. Florou: Financial Interests, Personal, Advisory Board, Consultant: Deciphera; Financial Interests, Personal, Advisory Board: Incyte. A. Morton: Financial Interests, Institutional, Full or part-time Employment, Employer: Jacobio Pharmaceuticals Inc. S. Liu: Financial Interests, Personal, Full or part-time Employment: Jacobio Pharmaceuticals Co., Ltd. S. Gadgeel: Financial Interests, Personal, Advisory Board: AstraZeneca, Amgen, Genentech/Roche, Bristol Myers Squibb, Pfizer, Daiichi, Mirati, Lilly, Merck, Eisai, Gilead, Regeneron, Takeda, Bayer; Financial Interests, Personal, Other, Data Safety Monitoring Board: AstraZeneca; Financial Interests, Personal, Other, Travel support to attend WCLC 2023 for oral presentation: Mirati, Merck; Financial Interests, Institutional, Local PI: AstraZeneca, Nuvalent, Tango Pharmaceuticals, Genentech/Roche, Genmab, Nimbus, Daiichi, Janssen, Amgen, Bayer, Mirati, BioAtla, Pfizer, D3 Bio, Debio Pharma, Arrivent, Grail, Iovance, Jacobio, Kymera, Keza Pharmaceuticals, AbbVie, Amgen, Novita, Regeneron, Turning Point, Verastem; Financial Interests, Institutional, Steering Committee Member: Genmab; Financial Interests, Personal, Local PI: Arcus, Effector. All other authors have declared no conflicts of interest.
Resources from the same session
630P - Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)
Presenter: Hans Gelderblom
Session: Poster session 01
631P - Phase Ib expansion study of CX-5461 in patients with solid tumours and BRCA2 and/or PALB2 mutation
Presenter: Pamela Soberanis Pina
Session: Poster session 01
632P - Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 01
633P - First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
Presenter: Christopher Lieu
Session: Poster session 01
634P - First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors
Presenter: Xiangdong Cheng
Session: Poster session 01
635P - The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors
Presenter: Jie Wang
Session: Poster session 01
636P - Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
Presenter: Benjamin Kong
Session: Poster session 01
637P - AC699, a novel chimeric estrogen receptor degrader, in a phase I study in breast cancer
Presenter: Erika Hamilton
Session: Poster session 01
638P - Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center
Presenter: Apostolia Maria Tsimberidou
Session: Poster session 01
639P - Serial ctDNA profiling as a catalyst for tailored therapeutics in advanced cancer: Analysis of two precision medicine studies
Presenter: Sophie Cousin
Session: Poster session 01